Ken Griffin Taysha Gene Therapies, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 65,200 shares of TSHA stock, worth $223,636. This represents 0.0% of its overall portfolio holdings.

Number of Shares

65,200

Previous 29,300 122.53%

Holding current value

$223,636

Previous $51,000 266.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.43 - $3.25 $3.29 Million - $7.47 Million	-2,297,359 Reduced 99.99%	197 $0
Q4 2023 Feb 14, 2024	BUY	$1.33 - $2.88 $3.06 Million - $6.62 Million	2,297,556 New	2,297,556 $4.07 Million
Q1 2023 May 15, 2023	SELL	$0.65 - $2.3 $112,071 - $396,561	-172,418 Reduced 93.85%	11,293 $9,000
Q4 2022 Feb 14, 2023	BUY	$1.89 - $2.44 $251,617 - $324,839	133,131 Added 263.21%	183,711 $415,000
Q3 2022 Nov 14, 2022	SELL	$1.89 - $4.94 $113,420 - $296,454	-60,011 Reduced 54.26%	50,580 $97,000

Q2 2022 Aug 15, 2022	SELL	$2.47 - $6.77 $242,450 - $664,529	-98,158 Reduced 47.02%	110,591 $411,000
Q1 2022 May 16, 2022	BUY	$5.22 - $11.86 $899,990 - $2.04 Million	172,412 Added 474.48%	208,749 $1.36 Million
Q4 2021 Feb 14, 2022	BUY	$11.43 - $19.2 $415,331 - $697,670	36,337 New	36,337 $423,000
Q1 2021 May 17, 2021	SELL	$20.3 - $31.75 $725,765 - $1.14 Million	-35,752 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$19.14 - $28.13 $4.01 Million - $5.89 Million	-209,282 Reduced 85.41%	35,752 $949,000
Q3 2020 Nov 16, 2020	BUY	$22.4 - $24.47 $5.49 Million - $6 Million	245,034 New	245,034 $5.49 Million

Others Institutions Holding TSHA

# of Institutions

111

Shares Held

109M

Call Options Held

108K

Put Options Held

158K

View Full List

About Taysha Gene Therapies, Inc.

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $166M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

More about TSHA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account